Skip to main content

Figure 2.

Figure 2

Time to progression (TTP) in all 27 patients treated with sorafenib. The median TTP was 4.9 months, and the 6‐month survival rate was 46.2%. Overall survival (OS) in the 27 patients treated with sorafenib. The median OS period was 15.6 months, and the 1‐year survival rate was 59.3%.